The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Nakao, N., Yoshimura, A., Morita, H., Takada, M., Kayano, T., & Ideura, T. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12229-5 · Cited by 970
RetractedBrenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011489 · Cited by 2,873
[Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
Parving, H., Lehnert, H., Brøchner‐Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · PubMed · Cited by 2,535
Epstein, F. H., Brenner, B. M., Meyer, T. W., & Hostetter, T. H. (1982) · New England Journal of Medicine · doi:10.1056/nejm198209093071104 · Cited by 2,075
Maschio, G., Alberti, D., Janin, G., Locatelli, F., Mann, J. F. E., Motolese, M., Ponticelli, C., Ritz, E., & Zucchelli, P. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604113341502 · Cited by 1,766
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 1,406
Peterson, J. C., Adler, S., Burkart, J. M., Greene, T., Hebert, L. A., Hunsicker, L. G., King, A. J., Klahr, S., Massry, S. G., Seifter, J. L., et al. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-10-199511150-00003 · Cited by 1,342
Pathophysiology of Progressive Nephropathies
Remuzzi, G., & Bertani, T. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811123392007 · Cited by 1,269
Jafar, T. H., Schmid, C. H., Landa, M., Giatras, I., Toto, R., Remuzzi, G., Maschio, G., Brenner, B. M., Kamper, A., Zucchelli, P., et al. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-2-200107170-00007 · Cited by 1,092
Mogensen, C. E., Neldam, S., Tikkanen, I., Oren, S., Viskoper, R., Watts, R. W., & Cooper, M. E. (2000) · BMJ · doi:10.1136/bmj.321.7274.1440 · Cited by 1,037
Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass.
Anderson, S., Meyer, T. W., Rennke, H. G., & Brenner, B. M. (1985) · Journal of Clinical Investigation · doi:10.1172/jci112013 · Cited by 932
Bakris, G. L., & Weir, M. R. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.5.685 · Cited by 823
Viberti, G., & Wheeldon, N. M. (2002) · Circulation · doi:10.1161/01.cir.0000024416.33113.0a · Cited by 802
The renin-angiotensin-aldosterone system: Past, present and future
Vecsei, P., Hackenthal, E., & Ganten, D. (1978) · Klinische Wochenschrift · doi:10.1007/bf01477448 · Cited by 604
Tsutsumi, Y., Matsubara, H., Masaki, H., Kurihara, H., Murasawa, S., Takai, S., Miyazaki, M., Nozawa, Y., Ozono, R., Nakagawa, K., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7886 · Cited by 561
Angiotensin Receptors and Their Antagonists
Goodfriend, T. L., Elliott, M. E., & Catt, K. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199606203342507 · Cited by 558
Mineralocorticoid Blockade Reduces Vascular Injury in Stroke-Prone Hypertensive Rats
Rocha, R., Chander, P. N., Khanna, K., Zuckerman, A., & Stier, C. T. (1998) · Hypertension · doi:10.1161/01.hyp.31.1.451 · Cited by 496
Aldosterone: A Mediator of Myocardial Necrosis and Renal Arteriopathy
Rocha, R. (2000) · Endocrinology · doi:10.1210/en.141.10.3871 · Cited by 475
Erdös, E. G. (1990) · Hypertension · doi:10.1161/01.hyp.16.4.363 · Cited by 412
The renin-angiotensin-aldosterone system: a specific target for hypertension management
Weir, M. (1999) · American Journal of Hypertension · doi:10.1016/s0895-7061(99)00103-x · Cited by 407
Tissue angiotensin system in cardiovascular medicine. A paradigm shift?
Dzau, V. J., & Re, R. (1994) · Circulation · doi:10.1161/01.cir.89.1.493 · Cited by 301
Angiotensin II Directly Stimulates ENaC Activity in the Cortical Collecting Duct via AT1 Receptors
Peti-Peterdi, J., Warnock, D. G., & Bell, P. D. (2002) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000013292.78621.fd · Cited by 298
Renin???angiotensin system: a dual tissue and hormonal system for cardiovascular control
Johnston, C. I. (1992) · Journal of Hypertension · doi:10.1097/00004872-199212000-00002 · Cited by 275
Chrysostomou, A., & Becker, G. (2001) · New England Journal of Medicine · doi:10.1056/nejm200109203451215 · Cited by 267
Schepkens, H., Vanholder, R., Billiouw, J.-M., & Lameire, N. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00642-8 · Cited by 262
Diabetic nephropathy in type II diabetes
Ritz, E., & Stefanski, A. (1996) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(96)90538-7 · Cited by 261
Cooper, M. E., Boner, G., Cao, Z., Kawachi, H., Bonnet, F., & Allen, T. J. (2001) · Diabetologia · doi:10.1007/s001250100546 · Cited by 249
Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy
Russo, D., Minutolo, R., Pisani, A., Esposito, R., Signoriello, G., Andreucci, M., & Balletta, M. M. (2001) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2001.25176 · Cited by 247
Baillière's clinical endocrinology and metabolism
ScienceDirect (1998) · Cited by 229
Diabetic nephropathy: Prevention and treatment
Parving, H.-H. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00020.x · Cited by 226
Dual Blockade of the Renin-Angiotensin System in Diabetic Nephropathy
Rossing, K., Christensen, P. K., Jensen, B. R., & Parving, H.-H. (2002) · Diabetes Care · doi:10.2337/diacare.25.1.95 · Cited by 205
Liu, F. Y., & Cogan, M. G. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114174 · Cited by 204
Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation.
Singh, R., Alavi, N., Singh, A. K., & Leehey, D. J. (1999) · Diabetes · doi:10.2337/diabetes.48.10.2066 · Cited by 197
Tubular fluid concentrations and kidney contents of angiotensins I and II in anesthetized rats.
Navar, L. G., Lewis, L., Hymel, A., Braam, B., & Mitchell, K. D. (1994) · Journal of the American Society of Nephrology · doi:10.1681/asn.v541153 · Cited by 192
Safety of the combination of valsartan and benazepril in patients with chronic renal disease
Ruilope, L. M., Aldigier, J. C., Ponticelli, C., Oddou-Stock, P., Botteri, F., & Mann, J. F. (2000) · Journal of Hypertension · doi:10.1097/00004872-200018010-00013 · Cited by 179
Cell biology and genetics of angiotensin in cardiovascular disease
Dzau, V. (1994) · Journal of Hypertension - Supplement · doi:10.1097/00004872-199407030-00002 · Cited by 173
The paradox of the renin-angiotensin system in chronic renal disease
Rosenberg, M. E., Smith, L. J., Correa‐Rotter, R., & Hostetter, T. H. (1994) · Kidney International · doi:10.1038/ki.1994.52 · Cited by 157
Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity
Feria, I. G., Pichardo, I., Juárez, P., Ramírez, V., González, M. A., Uribe, N., García-Torres, R., López‐Casillas, F., Gamba, G., & Bobadilla, N. A. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00707.x · Cited by 150
The biochemistry of the renin-angiotensin system and its role in hypertension
Skeggs, L. T., Dorer, F. E., Kahn, J. R., Lentz, K. E., & Levine, M. (1976) · The American Journal of Medicine · doi:10.1016/0002-9343(76)90888-3 · Cited by 139
Benigni, A., Tomasoni, S., Gagliardini, E., Zoja, C., Grunkemeyer, J. A., Kalluri, R., & Remuzzi, G. (2001) · Journal of the American Society of Nephrology · doi:10.1681/asn.v125941 · Cited by 139
Peart, W. S. (1975) · New England Journal of Medicine · doi:10.1056/nejm197502062920609 · Cited by 138
Allen, T. J., Cao, Z., Youssef, S., Hulthén, U. L., & Cooper, M. E. (1997) · Diabetes · doi:10.2337/diacare.46.10.1612 · Cited by 135
Add-on angiotensin receptor blockade with maximized ACE inhibition
Agarwal, R. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00745.x · Cited by 131
ACE Inhibitors versus AT1 Receptor Antagonists in Patients with Chronic Renal Disease
Hilgers, K. F., & Mann, J. F. E. (2002) · Journal of the American Society of Nephrology · doi:10.1681/asn.v1341100 · Cited by 126
Renoprotection by ACE Inhibition or Aldosterone Blockade Is Blood Pressure–Dependent
Griffin, K. A., Abu‐Amarah, I., Picken, M. M., & BIDANI, A. K. (2003) · Hypertension · doi:10.1161/01.hyp.0000049881.25304.73 · Cited by 117
Angiotensin II Type 2 Receptor Inhibits Cell Proliferation and Activates Tyrosine Phosphatase
Tsuzuki, S., Matoba, T., Eguchi, S., et al. (1996) · Hypertension · doi:10.1161/01.hyp.28.5.916 · Cited by 102
Intrarenal angiotensin II generation and renal effects of AT1 receptor blockade.
Navar, L. G., Harrison‐Bernard, L. M., Imig, J. D., Wang, C. T., Červenka, L., & Mitchell, K. D. (1999) · PubMed · Cited by 98
Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies
Luño, J., Barrio, V., Goicoechea, M. Á., González, C., de Vinuesa, S. G., Gómez-Preciado, F., Bernis, C., Espinosa, M., Ahijado, F. J., Gómez, J., et al. (2002) · Kidney International · doi:10.1046/j.1523-1755.62.s82.10.x · Cited by 78
Luft, F. C. (2002) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-200201000-00009 · Cited by 74
Hostetter, T. H., Rosenberg, M. E., Ibrahim, H. N., & Juknevicius, I. (2001) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-200101000-00016 · Cited by 72
Nephrotoxicity of increased glomerular protein traffic
Abbate, M. (1999) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/14.2.304 · Cited by 65
Effect of candesartan cilexetil (TCV-116) in rats with chronic renal failure
Noda, M., Matsuo, T., Fukuda, R., Ohta, M., Nagano, H., Shibouta, Y., Naka, T., Nishikawa, K., & Imura, Y. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00614.x · Cited by 48
Angiotensin II receptor blockade and end-organ protection
Chung, O., & Unger, T. (1999) · American Journal of Hypertension · doi:10.1016/s0895-7061(99)00218-6 · Cited by 46
Prevention of Renal Injury in Diabetic MWF Rats by Angiotensin II Antagonism
Remuzzi, A., Fassi, A., Sangalli, F., Malanchini, B., Mohamed, E. I., Bertani, T., & Remuzzi, G. (1998) · Nephron Experimental Nephrology · doi:10.1159/000020502 · Cited by 41
The renin-angiotensin system in the vessel wall
Müller, D. N., & Luft, F. C. (1998) · Basic Research in Cardiology · doi:10.1007/s003950050194 · Cited by 38
Epstein, M., Buckalew, V. M., Altamirano, J. H., Roniker, B., Krause, S. L., & Kleiman, J. H. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)81115-9 · Cited by 36
Pressure Natriuresis in AT2 Receptor–Deficient Mice with L-NAME Hypertension
Obst, M., Groß, V., Janke, J., Wellner, M., Schneider, W., & Luft, F. C. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000043904.26730.11 · Cited by 31
6 The renin—angiotensin—aldosterone system in volume control
Mitchell, K. D., & Navar, L. G. (1989) · Baillière s Clinical Endocrinology and Metabolism · doi:10.1016/s0950-351x(89)80009-6 · Cited by 27
Regulation of Na+ permeability by aldosterone.
Garty, H. (1992) · PubMed · Cited by 27
Schepkens, H. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00997-4 · Cited by 8
Cited by
Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction
Anavekar, N. S., McMurray, J. J. V., Velazquez, E. J., Solomon, S. D., Kober, L., Rouleau, J.-L., White, H. D., Nordlander, R., Maggioni, A., Dickstein, K., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041365 · Cited by 1,917
Physiology of Local Renin-Angiotensin Systems
Paul, M., Poyan Mehr, A., & Kreutz, R. (2006) · Physiological Reviews · doi:10.1152/physrev.00036.2005 · Cited by 1,739
Angiotensin II revisited: new roles in inflammation, immunology and aging
Benigni, A., Cassis, P., & Remuzzi, G. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000080 · Cited by 757
Renin-angiotensin-aldosterone (RAAS): The ubiquitous system for homeostasis and pathologies
Patel, S., Rauf, A., Khan, H., & Abu-Izneid, T. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.07.091 · Cited by 626
Devaux, C. A., Rolain, J.-M., & Raoult, D. (2020) · Journal of Microbiology, Immunology and Infection · doi:10.1016/j.jmii.2020.04.015 · Cited by 476
Metadata
- Authors
- Brewster, U. C., & Perazella, M. A.
- Venue
- The American Journal of Medicine
- Publisher
- Elsevier BV
- Published
- 2004-02
- Volume
- 116
- Issue
- 4
- Pages
- 263-272
- ISSN
- 0002-9343 (ISSN-L)
- OpenAlex
- W2036960544
- Cited by
- 390
- References
- 66
- FWCI
- 14.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.